Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus FEXOFENADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus FEXOFENADINE HYDROCHLORIDE.
CLARITIN REDITABS vs FEXOFENADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Selective peripheral H1-receptor antagonist; inhibits histamine release from mast cells and basophils, reducing allergic symptoms without significant central nervous system penetration.
10 mg orally once daily.
60 mg orally twice daily or 180 mg orally once daily; maximum 180 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
14.4 hours in healthy adults; prolonged in renal impairment (up to 58 hours in end-stage renal disease) requiring dose adjustment.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Primarily fecal (80%) with approximately 11% renal excretion of unchanged drug. Biliary excretion contributes to fecal elimination.
Category C
Category A/B
Antihistamine
Antihistamine